Probiotic with vedolizumab for moderate ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests whether adding a special probiotic (VSL#3) to vedolizumab helps people with moderate ulcerative colitis more than vedolizumab alone. You may qualify if you are already planning to start vedolizumab and haven't responded well enough to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have had ulcerative colitis (UC) for at least 3 months and currently have moderate symptoms (Mayo score 6–10).
- You are planning to start or restart vedolizumab, and you haven't used it in the past year.
- You have already tried at least one standard UC treatment (like mesalamine or azathioprine) and it didn't work well enough or you couldn't tolerate it.
- You can avoid taking antibiotics, probiotics, or steroid therapy for at least 2 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This study tests whether adding a herbal supplement called CurQD to the standard treatment vedolizumab can help control ulcerative colitis symptoms better than vedolizumab alone. It aims to see if the combination reduces inflammation and improves quality of life for people with active disease.
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.